Momenta Pharmaceuticals Inc (MNTA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Momenta Pharmaceuticals Inc (Momenta) is a biotechnology company which specializes in the structural analysis, characterization, and design of complex pharmaceuticals. The companys products include Glatopa; and Enoxaparin Sodium Injection. Its pipeline portfolio encompasses candidates to substitute Copaxone 40 mg/mL, Humira, and Orencia; an anti-FcRn antibody; selective immune-modulator of Fc receptors; hyper-sialylated IVIg as well as investigational candidate for the treatment of pancreatic cancer. The company utilizes its technology for developing generic versions of biosimilars, complex drugs, and potentially interchangeable biologics, and also in the discovery and development of therapeutics for various cancers and autoimmune indications. Momenta is headquartered in Cambridge, Massachusetts, the US.

Momenta Pharmaceuticals Inc (MNTA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

It derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 5
List of Figures 5
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Momenta Pharma Exercises Option To Acquire Novel Antibodies Program from AnaptysBio 11
Partnerships 12
Momenta Pharma Enters into Co-Development Agreement with AnaptysBio for Antibody Discovery 12
Licensing Agreements 13
AbbVie Enters into Licensing Agreement with Momenta Pharma 13
CSL Enters into Licensing Agreement with Momenta Pharma 14
Mylan Ireland Enters into Licensing Agreement with Momenta Pharma 16
Sialix Enters Into Licensing Agreement With Momenta Pharma For Monoclonal Antibody Therapeutic Program 18
Equity Offering 19
Momenta Pharma Plans to Raise USD65 Million in Public Offering of Shares 19
Momenta Pharma Raises USD158 Million Public Offering of Shares 20
Momenta Pharma Raises USD75 Million in Public Offering of Shares 22
Momenta Pharmaceuticals Inc - Key Competitors 23
Momenta Pharmaceuticals Inc - Key Employees 24
Momenta Pharmaceuticals Inc - Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Nov 07, 2018: Momenta Pharmaceuticals reports third quarter 2018 financial results and provides corporate update 26
Aug 09, 2018: Momenta Pharmaceuticals announces second quarter 2018 financial results 28
May 08, 2018: Momenta Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update 30
Feb 21, 2018: Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Provides Corporate Update 33
Nov 01, 2017: Momenta Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update 36
Aug 02, 2017: Momenta Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update 39
May 02, 2017: Momenta Pharmaceuticals Reports First Quarter 2017 Financial Results 42
Feb 21, 2017: Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results 45
Corporate Communications 48
Oct 02, 2017: Momenta Pharmaceuticals Promotes Ganesh V. Kaundinya as Chief Operating Officer and Chief Scientific Officer 48
Jun 01, 2017: Momenta Pharmaceuticals Appoints Santiago Arroyo, M.D., Ph.D. as Chief Medical Officer 49
Legal and Regulatory 50
Mar 21, 2018: Amphastar Announces Final Judgment in the Patent Litigation against Momenta Pharmaceuticals and Sandoz 50
Government and Public Interest 51
Jan 06, 2017: Momenta Provides Year-End 2016 Corporate Update 51
Product News 53
05/17/2018: Momenta Pharmaceuticals Announces Presentation on M281, an Anti-FcRn Monoclonal Antibody, at 11th International Congress on Autoimmunity 53
01/03/2018: Momenta and Mylan Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA (aflibercept) 54
Clinical Trials 55
Jan 05, 2018: Momenta Pharmaceuticals Reports Positive Top-Line Phase 1 Data Showing Proof of Mechanism for M281, an Anti-FcRn Monoclonal Antibody, in Healthy Volunteers 55
Appendix 56
Methodology 56
About GlobalData 56
Contact Us 56
Disclaimer 56

List Of Tables


Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Momenta Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Momenta Pharma Exercises Option To Acquire Novel Antibodies Program from AnaptysBio 11
Momenta Pharma Enters into Co-Development Agreement with AnaptysBio for Antibody Discovery 12
AbbVie Enters into Licensing Agreement with Momenta Pharma 13
CSL Enters into Licensing Agreement with Momenta Pharma 14
Mylan Ireland Enters into Licensing Agreement with Momenta Pharma 16
Sialix Enters Into Licensing Agreement With Momenta Pharma For Monoclonal Antibody Therapeutic Program 18
Momenta Pharma Plans to Raise USD65 Million in Public Offering of Shares 19
Momenta Pharma Raises USD158 Million Public Offering of Shares 20
Momenta Pharma Raises USD75 Million in Public Offering of Shares 22
Momenta Pharmaceuticals Inc, Key Competitors 23
Momenta Pharmaceuticals Inc, Key Employees 24
Momenta Pharmaceuticals Inc, Subsidiaries 25

List Of Figures


Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Momenta Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

2020 Momenta Pharmaceuticals Performance, Capabilities, Goals and Strategies

This report is part of the Competitive Analysis Series, which includes assessments of more than 1,000 companies worldwide.The report provides significant competitor information, analysis and insight critical to the development

USD 950 View Report

2019 Pharmaceutical Competitive Intelligence: Momenta Pharmaceuticals Performance, Capabilities, Goals and Strategies

This report is part of the Competitive Analysis Series, which includes current assessments of more than 1,000 companies worldwide. The assessments include all or some of the following: Organization

USD 950 View Report

2020 Momenta Pharmaceuticals Performance, Capabilities, Goals and Strategies

This report is part of the Competitive Analysis Series, which includes assessments of more than 1,000 companies worldwide.The report provides significant competitor information, analysis and insight critical to the development

USD 950 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available